CYT 0.00 Cyteir Therapeutics, Inc.
| Range: | 1.65-3.19 | Vol Avg: | 167616 | Last Div: | 0 | Changes: | -0.07 |
| Beta: | 0.1 | Cap: | 0.11B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 18 2021 | Empoloyees: | 46 | ||
| CUSIP: | 550241103 | CIK: | 0001662244 | ISIN: | US23284P1030 | Country: | US |
| CEO: | Dr. Markus F. Renschler M.D. | Website: | https://cyteir.com | ||||
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow